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Now Gosport – what next? 
Lucy Pocock, Karen Forbes, Colette Reid and Sarah Purdy 
 
Last month saw the, long awaited, publication of the independent inquiry into deaths 
at Gosport War Memorial Hospital between 1989 and 2000. The inquiry panel, led by 
The Right Reverend James Jones KBE, concluded that “the lives of over 450 people 
were shortened as a direct result of the pattern of prescribing and administering 
opioids”.1  
Following Dr Harold Shipman’s conviction for murder in 2000, and the publication of 
the Shipman Inquiry, concerns were raised about the regulation of GPs in the UK, 
particularly in relation to opioid prescribing. Not surprisingly, there is evidence that 
the case had impacted upon the prescribing practices of doctors, particularly when 
treating non-cancer patients at the end of life.   
 
In 2005, shortly after Shipman committed suicide in prison, a small survey of UK 
doctors found that nearly half of the respondents (46%) had new uncertainty about 
prescribing opioids and sedation for terminally ill patients and 17% of GPs stated that 
their practice had changed a lot due to concerns about facing a charge of unlawful 
killing.2 More recently, a qualitative study looking at dyspnoea management in 
advanced COPD suggested that the Shipman case had exposed clinicians’ implicit 
beliefs regarding opioid prescribing, most worryingly the unfounded idea that they 
might cause a patient’s death directly by prescribing opioids, appropriately, in a 
palliative care context.3 Gardiner et al found that GPs lacking confidence or expertise 
in opioid prescribing required significant input from specialist palliative care teams, 
with some GPs describing how they often simply ‘‘handed over’’ pain control at the 
end of life to their specialist colleagues.4 
Concerns among the public and health professionals over the use of opioids at the 
end of life and myths around their role in hastening death continue, as raised in the 
Neuberger review of the Liverpool Care Pathway.5 The Doctrine of Double Effect 
(DDE) is often used as an ethical justification for the use of opioids to treat symptoms 
at the end of life, recognising that they might, as a secondary effect, shorten life. The 
doctrine states this is permissible provided the intention is to achieve symptom relief, 
rather than to cause death.6 There is considerable evidence that this concern is 
irrelevant; Thorns and Sykes found, in their study of 238 hospice patients, that 
appropriate use of opioids for symptom control did not shorten life and “there is little if 
any need to invoke the DDE”.7 
The doctor at the centre of the Gosport inquiry, Dr Jane Barton, was a GP working as 
a part-time clinical assistant at Gosport War Memorial Hospital between 1988 and 
2000. In January 2010 the General Medical Council found her guilty of serious 
professional misconduct (10 years after they were first made aware of concerns 
regarding her practice), but she was not removed from the medical register. She 
retired soon after. The inquiry panel concluded that one of the issues with previous 
investigations into the events at Gosport was the “exclusive focus” on Dr Barton and 
her conduct, which ignored the wider “significant systemic problems”. We know that 
concerns were raised with senior doctors and managers, so assume that they were 
aware of, and presumably not concerned by, her practice. This was attributed, in part, 
to the shadow cast by the Shipman case and the perception that she might be another 
“rogue doctor” or “lone wolf”.1 
The patients investigated in the Gosport inquiry were not admitted for end of life care, 
and opioids were prescribed and administered to them without appropriate clinical 
indication. Thus, although these patients were not imminently dying, as with the 
Shipman case, we can expect some filtering down to the beliefs, prescribing culture 
and practices of GPs. We believe that this highlights an urgent need for further training 
to address these anxieties and prevent a potential negative impact on the quality of 
end of life care being provided by generalists in the community.  
Recent work by Selman et al identified several educational barriers to GPs providing 
end of life care, including inadequate exposure during training, the challenge of 
keeping knowledge up to date and maintaining skills, and low confidence about their 
abilities.8 Their work suggests a move away from formal education methods and 
identifies the need for practice-based mentorship and/or apprenticeship models in 
education in end of life care. 
With a national drive to increase the number of people who are dying at home, GPs 
and their community nursing colleagues will, once again, be in a position of greater 
responsibility for managing care at the end of life. To achieve this, good relationships 
with specialist palliative care services will be required, in addition to appropriate 
guidance and the confidence to put it in place – which we think will be shaken by the 
Gosport report. Good communication with patients and their families will also be 
necessary, since some of the mainstream press coverage9 is likely to have worsened 
lay misunderstanding and escalated their concerns about the use of medication in the 
dying patient.5,10 
It is beyond the remit of this editorial, but this case once again highlights the need for 
further work to be done within the NHS regarding whistle-blowing. Staff in Gosport, 
who had concerns about patient safety, felt unable to make their views heard. We 
welcome the Health Secretary’s very recent espoused commitment to this. However, 
if we are to prevent another Gosport then whistle-blowers must be fully supported in 
reporting both “lone wolves” and systemic failings and protected by employment law 
when they do.  
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